NCT05162937View on ClinicalTrials.gov

to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

July 30, 2021

Study Completion Date

November 2, 2021

Conditions

Axial Spondyloarthritis

Interventions

BIOLOGICAL

IL-17A antibody

Recombinant fully human IgG4 anti-IL-17A monoclonal antibody drug

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY

NCT05162937 - to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis | Biotech Hunter | Biotech Hunter